Citations

Clear

1526 citation(s) found for "Sun, Yu".

Demographic Trends From 2005 to 2015 Among Physicians With Accreditation Council for Graduate Medical Education–Accredited Anesthesiology Training and Active Medical Licenses
Harman, Ann E., Keegan, Mark T. , Macario, Alex, Minhaj, Mohammed , Chaudhry, Humayun J. , Young, Aaron , Zhou, Yan , Sun, Huaping , Wang, Ting , Warner, David O.

Mayo Clinic

Anesthesia & Analgesia | January 14, 2021 | Volume: 132 | Issue: 5 | Pages: 1457-1464

10.1213/ane.0000000000005332 | PMID 33438967 Get It

BACKGROUND: A temporary decrease in anesthesiology residency graduates that occurred around the turn of the millennium may have workforce implications. The aims of this study are to describe, between 2005 and 2015, (1) demographic changes in the workforce of physicians trained as anesthesiologists; (2) national and state densities of these physicians, as well as temporal changes in the densities; and (3) retention of medical licenses by mid- and later-career anesthesiologists. METHODS: Using records from the American Board of Anesthesiology and state medical and osteopathic boards, the numbers of licensed physicians aged 30–59 years who had completed Accreditation Council for Graduate Medical Education–accredited anesthesiology residency training were calculated cross-sectionally for 2005, 2010, and 2015. Demographic trends were then described. Census data were used to calculate national and state densities of licensed physicians. Individual longitudinal data were used to describe retention of medical licenses among older physicians. RESULTS: The number of licensed physicians trained as anesthesiologists aged 30–59 years increased from 32,644 in 2005 to 36,543 in 2010 and 36,624 in 2015, representing a national density of 1.10, 1.18, and 1.14 per 10,000 population in those years, respectively. The density of anesthesiologists among states ranged from 0.37 to 3.10 per 10,000 population. The age distribution differed across the years. For example, anesthesiologists aged 40–49 years predominated in 2005 (47%), but by 2015, only 31% of anesthesiologists were aged 40–49 years. The proportion of female anesthesiologists grew from 22% in 2005, to 24% in 2010, and to 28% in 2015, particularly among early-career anesthesiologists. For anesthesiologists with licenses in 2005, the number who still had active licenses in 2015 decreased by 9.6% for those aged 45–49 years, by 14.1% for those aged 50–54 years, and by 19.7% for those aged 55–59 years. CONCLUSIONS: The temporary decrease in anesthesiology residency graduates around the turn of the 21st century decreased the proportion of anesthesiologists who were midcareer as of 2015. This may affect the future availability of senior leaders as well as the future overall workforce in the specialty as older anesthesiologists retire. National efforts to plan for workforce needs should recognize the geographical variability in the distribution of anesthesiologists.
Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin
Sun, Zhuoxin , Verma, Amit , Bennett, John M. , Komrokji, Rami S. , McGraw, Kathy L. , Maciejewski, Jaroslaw P. , Altman, Jessica K. , Cheema, P. , Claxton, David F. , Luger, Selina M. , Mattison, Ryan J. , Wassenaar, Timothy R. , Schiffer, Charles A. , Litzow, Mark R. , Tallman, Martin S. , Verma, Amit , Verma, Amit , Komrokji, Rami S , Cheema, Puneet S , Claxton, David F , Luger, Selina M , Artz, Andrew S , List, Alan F. , Artz, Andrew

Mayo Clinic

Journal of Clinical Oncology | January 13, 2021 | Volume: 39 | Issue: 9 | Pages: 1001-1009

10.1200/jco.20.01691 | PMID 33439748 Get It

PURPOSE Impaired response to erythropoietin underlies ineffective erythropoiesis and anemia in myelodysplastic syndromes (MDS). We investigated whether treatment with lenalidomide (LEN), which augments erythropoietin receptor signaling in vitro, can restore and improve hemoglobin response to epoetin (EPO) alfa in patients with lower-risk, non-del(5q) MDS who have anemia that is refractory to or have low probability of benefit from treatment with recombinant erythropoietin. METHODS In a phase III, US intergroup trial, we randomly assigned patients to receive either LEN and EPO alfa or LEN alone following stratification by serum erythropoietin concentration and prior erythropoietin treatment. RESULTS A total of 195 evaluable patients were randomly assigned: 99 patients to the LEN-EPO alfa cohort and 96 to LEN alone. After four cycles of treatment, the primary end point of major erythroid response (MER) was significantly higher (28.3%) with the combination compared with LEN alone (11.5%) ( P = .004). Among 136 patients who completed 16 weeks of study treatment, 38.9% and 15.6% achieved MER, respectively ( P = .004). Additionally, minor erythroid response was achieved in 18.2% and 20.8% of patients, for an overall erythroid response rate of 46.5% versus 32.3%. Among LEN nonresponders, 38 crossed over to the addition of EPO alfa with 10 patients (26.3%) achieving a MER. Responses to the combined treatment were highly durable with a median MER duration of 23.8 months compared with 13 months with LEN alone. CONCLUSION LEN restores sensitivity to recombinant erythropoietin in growth factor–insensitive, lower-risk, non-del(5q) MDS, to yield a significantly higher rate and duration of MER compared with LEN alone (funded by the National Cancer Institute; E2905 ClinicalTrials.gov identifier: NCT02048813 ).
Tissue-resident CD4 + T helper cells assist the development of protective respiratory B and CD8 + T cell memory responses
Son, Young Min , Cheon, In Su , Wu, Yue , Li, Chaofan , Wang, Zheng , Gao, Xiaochen , Takahashi, Yoshimasa , Fu, Yang-Xin , Dent, Alexander L. , Kaplan, Mark H. , Fu, Yang‐Xin , Fu, Yang-Xin , Dent, Alexander L , Kaplan, Mark H , Taylor, Justin J , Sun, Jie , Li, Chaofan , Chen, Yao , Taylor, Justin J. , Cui, Weiguo , Sun, Jie

Mayo Clinic

Science Immunology | January 8, 2021 | Volume: 6 | Issue: 55 | Pages: No page available

10.1126/sciimmunol.abb6852 | PMID 33419791 Get It

Identification of a CD4 + helper T cell population providing in situ help to B and CD8 + T cells in the respiratory mucosa.
T resident helper cells promote humoral responses in the lung
Swarnalekha, Nivedya , Schreiner, David , Litzler, Ludivine C. , Iftikhar, Saadia, Kirchmeier, Daniel , Künzli, Marco , Son, Young Min , Sun, Jie , Moreira, Étori Aguiar , King, Carolyn G. , Sun, Jie

Mayo Clinic

Science Immunology | January 8, 2021 | Volume: 6 | Issue: 55 | Pages: No page available

10.1126/sciimmunol.abb6808 | PMID 33419790 Get It

Analysis of CD4 + T cell heterogeneity in the lung uncovers a Bcl6-dependent subset that supports mucosal antibody production.
Integrated Molecular Characterization of Fumarate Hydratase–deficient Renal Cell Carcinoma
Sun, Guangxi , Liang, Jiayu, Pan, Xiuyi , Zhu, Sha , Liu, Zhenhua, Armstrong, Cameron M. , Lin, Wei, Liao, Banghua , Lin, Tianhai , Zhang, Mengni , Zheng, Linmao , Yin, Xiaoxue , Shen, Pengfei , Zhao, Jinge , Dai, Jindong, Shen, Yali, Li, Zhiping , Liu, Jiyan , Chen, Junru , Ni, Yuchao , Qin, Dan , Yang, Ling , Wei, Qiang , Li, Xiang , Zhou, Qiao , Yao, Jin , Chen, Ni , Zeng, Hao , Wang, Zhipeng , Liu, Zhenhua , Huang, Rui , Shen, Pengfei , Zhu, Sha , Chen, Junru , Wang, Zhipeng , Zhang, Xingming , Chen, Jianhui , Lin, Wei, Nie, Ling , Zhang, Haoran , Wang, Zhipeng , Zhu, Xudong , Chen, Yahong , Huang, Haojie

Mayo Clinic

Clinical Cancer Research | January 7, 2021 | Volume: 27 | Issue: 6 | Pages: 1734-1743

10.1158/1078-0432.ccr-20-3788 | PMID 33414138 Get It

AbstractPurpose:Fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC) is a rare but lethal subtype of RCC. Little is known about the genomic profile of FH-deficient RCC, and the therapeutic options for advanced disease are limited. To this end, we performed a comprehensive genomics study to characterize the genomic and epigenomic features of FH-deficient RCC.Experimental Design:Integrated genomic, epigenomic, and molecular analyses were performed on 25 untreated primary FH-deficient RCCs. Complete clinicopathologic and follow-up data of these patients were recorded.Results:We identified that FH-deficient RCC manifested low somatic mutation burden (median 0.58 mutations per megabase), but with frequent somatic copy-number alterations. The majority of FH-deficient RCCs were characterized by a CpG sites island methylator phenotype, displaying concerted hypermethylation at numerous CpG sites in genes of transcription factors, tumor suppressors, and tumor hallmark pathways. However, a few cases (20%) with low metastatic potential showed relatively low DNA methylation levels, indicating the heterogeneity of methylation pattern in FH-deficient RCC. Moreover, FH-deficient RCC is potentially highly immunogenic, characterized by increased tumor T-cell infiltration but high expression of immune checkpoint molecules in tumors. Clinical data further demonstrated that patients receiving immune checkpoint blockade–based treatment achieved improved progression-free survival over those treated with antiangiogenic monotherapy (median, 13.3 vs. 5.1 months; P = 0.03).Conclusions:These results reveal the genomic features and provide new insight into potential therapeutic strategies for FH-deficient RCC.
CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia
Ding, Husheng, McGehee, Cordelia D. , Kohorst, Mira A. , Koh, Brian D. , Venkatachalam, Annapoorna , Meng, X. Wei, Schneider, Paula A., Flatten, Karen S., Peterson, Kevin L. , Lee, Sun Hee , Patnaik, Mrinal M. , Webster, Jonathan , Karp, Judith E. , Pratz, Keith W. , Karnitz, Larry M., Vincelette, Nicole D. , Correia, Cristina , Webster, Jonathan A , Smith, B Douglas , Karp, Judith E , Kaufmann, Scott H , Correia, Cristina , Ghiaur, Gabriel , Smith, B. Douglas , Li, Hu , Kaufmann, Scott H. , Lee, Sun-Hee

Mayo Clinic

Cancer Research | January 7, 2021 | Volume: 81 | Issue: 10 | Pages: 2666-2678

10.1158/0008-5472.can-20-1504 | PMID 33414171 Get It

Abstract Although inhibitors of the kinases CHK1, ATR, and WEE1 are undergoing clinical testing, it remains unclear how these three classes of agents kill susceptible cells and whether they utilize the same cytotoxic mechanism. Here we observed that CHK1 inhibition induces apoptosis in a subset of acute leukemia cell lines in vitro, including TP53-null acute myeloid leukemia (AML) and BCR/ABL–positive acute lymphoid leukemia (ALL), and inhibits leukemic colony formation in clinical AML samples ex vivo. In further studies, downregulation or inhibition of CHK1 triggered signaling in sensitive human acute leukemia cell lines that involved CDK2 activation followed by AP1-dependent TNF transactivation, TNFα production, and engagement of a TNFR1- and BID-dependent apoptotic pathway. AML lines that were intrinsically resistant to CHK1 inhibition exhibited high CHK1 expression and were sensitized by CHK1 downregulation. Signaling through this same CDK2–AP1–TNF cytotoxic pathway was also initiated by ATR or WEE1 inhibitors in vitro and during CHK1 inhibitor treatment of AML xenografts in vivo. Collectively, these observations not only identify new contributors to the antileukemic cell action of CHK1, ATR, and WEE1 inhibitors, but also delineate a previously undescribed pathway leading from aberrant CDK2 activation to death ligand–induced killing that can potentially be exploited for acute leukemia treatment. Significance: This study demonstrates that replication checkpoint inhibitors can kill AML cells through a pathway involving AP1-mediated TNF gene activation and subsequent TP53-independent, TNFα-induced apoptosis, which can potentially be exploited clinically.
Esophageal motility disorders on high‐resolution manometry: Chicago classification version 4.0 ©
Yadlapati, Rena , Fox, Mark , Bredenoord, Albert J. , Gyawali, C. Prakash , Roman, Sabine , Babaei, Arash , Mittal, Ravinder K. , Rommel, Nathalie , Savarino, Edoardo , Smout, A. J. P. M. , Vaezi, Michael F. , Akiyama, Junichi, Bhatia, Shobna , Carlson, Dustin A. , Chen, Joan W. , Cisternas, Daniel , Cock, Charles , Defilippi, Claudia, Gonlachanvit, Sutep , Hebbard, Geoffrey , Jung, Kee Wook , Katz, Philip O. , Katzka, David A. , Khan, Anzalee , Kohn, Geoffrey P. , Lazarescu, Adriana , Lengliner, Johannes, Omari, Taher , Pohl, Daniel , Richter, Joel E. , Serra, Jordi , Sweis, Rami , Tack, Jan , Tatum, Roger P. , Vela, Marcelo F. , Wu, Justin C. Y. , Xiao, Yinglian , Pandolfino, John E. , Fox, Mark R , Gyawali, C P , Roman, S , Babaei, Arash , Mittal, Ravinder K , Sifrim, Daniel , Smout, André , Zerbib, Frank , Bor, Serhat , Carlson, Dustin A , Cisternas, Daniel , Cock, Charles , de Bortoli, Nicola , Fass, Ronnie , Ghoshal, Uday C , Jung, Kee Wook , Khan, Abraham , Omari, Taher , Park, Moo In , Penagini, Roberto , Serra, Jordi , Tack, Jan , Savarino, Edoardo , Kahrilas, Peter J. , Bor, Serhat , Coss‐Adame, Enrique , Bortoli, Nicola de , Fass, Ronnie , Ghoshal, Uday C. , Hani, Albis Cecilia , Mittal, Sumeet K. , Penagini, Roberto , Tutuian, Radu I. , Wong, Reuben K.

Mayo Clinic

Neurogastroenterology & Motility | December 29, 2020 | Volume: 33 | Issue: 1 | Pages: No page available

10.1111/nmo.14058 | PMID 33373111 Get It

Abstract Chicago Classification v4.0 (CCv4.0) is the updated classification scheme for esophageal motility disorders using metrics from high‐resolution manometry (HRM). Fifty‐two diverse international experts separated into seven working subgroups utilized formal validated methodologies over two‐years to develop CCv4.0. Key updates in CCv.4.0 consist of a more rigorous and expansive HRM protocol that incorporates supine and upright test positions as well as provocative testing, a refined definition of esophagogastric junction (EGJ) outflow obstruction (EGJOO), more stringent diagnostic criteria for ineffective esophageal motility and description of baseline EGJ metrics. Further, the CCv4.0 sought to define motility disorder diagnoses as conclusive and inconclusive based on associated symptoms, and findings on provocative testing as well as supportive testing with barium esophagram with tablet and/or functional lumen imaging probe. These changes attempt to minimize ambiguity in prior iterations of Chicago Classification and provide more standardized and rigorous criteria for patterns of disorders of peristalsis and obstruction at the EGJ.
Clinical longitudinal evaluation of COVID-19 patients and prediction of organ-specific recovery using artificial intelligence
Wang, Winston , Zhang, Charlotte L , Kang, Wei , Sang, Ye , Shen, Jun , Wang, Guangyu , Lozano, Alexander X.

Mayo Clinic

Precision Clinical Medicine | December 28, 2020 | Volume: 4 | Issue: 1 | Pages: 62-69

10.1093/pcmedi/pbaa040 | PMID 35693121 Get It

Abstract Within COVID-19 there is an urgent unmet need to predict at the time of hospital admission which COVID-19 patients will recover from the disease, and how fast they recover to deliver personalized treatments and to properly allocate hospital resources so that healthcare systems do not become overwhelmed. To this end, we have combined clinically salient CT imaging data synergistically with laboratory testing data in an integrative machine learning model to predict organ-specific recovery of patients from COVID-19. We trained and validated our model in 285 patients on each separate major organ system impacted by COVID-19 including the renal, pulmonary, immune, cardiac, and hepatic systems. To greatly enhance the speed and utility of our model, we applied an artificial intelligence method to segment and classify regions on CT imaging, from which interpretable data could be directly fed into the predictive machine learning model for overall recovery. Across all organ systems we achieved validation set area under the receiver operator characteristic curve (AUC) values for organ-specific recovery ranging from 0.80 to 0.89, and significant overall recovery prediction in Kaplan-Meier analyses. This demonstrates that the synergistic use of an artificial intelligence (AI) framework applied to CT lung imaging and a machine learning model that integrates laboratory test data with imaging data can accurately predict the overall recovery of COVID-19 patients from baseline characteristics.
1108: Secondary Analysis of Diagnostic Error Rate in Patients Requiring Rapid Response Team Activation
Pinevich, Yuliya , Soleimani, Jalal , Huang, Chanyan , Pickering, Brian W. , Herasevich, Svetlana , Barwise, Amelia , Dong, Yue , Herasevich, Vitaly , Gajic, Ognjen

Mayo Clinic

Critical Care Medicine | December 18, 2020 | Volume: 49 | Issue: 1 | Pages: 555-555

10.1097/01.ccm.0000730320.87252.fb Get It

1098: International Participant Satisfaction With the CERTAIN Structured Approach to Acute Care
Sun, Yuqiang, Heise, Katherine J., Gajić, Ognjen, Dong, Yue, Tekin, Aysun , Kashyap, Rahul , Niven, Alexander S. , Gajic, Ognjen

Mayo Clinic

Critical Care Medicine | December 18, 2020 | Volume: 49 | Issue: 1 | Pages: 550-550

10.1097/01.ccm.0000730280.27054.9e Get It